On 10 April 2022 the Australian Government assumed a caretaker role. The Government is now operating in accordance with the Caretaker Conventions, pending the outcome of the 2022 federal election. See Information on Caretaker Conventions. On 10 April 2022 the Australian Government assumed a caretaker role. The Government is now operating in accordance with the Caretaker Conventions, pending the outcome of the 2022 federal election. See Information on Caretaker Conventions.

Updates on 27/09/2021

Administration of vaccines

Guidance on intradermal injection expanded.

Catch-up vaccination

Guidance on MenB vaccine minimum intervals updated.

Cholera

Additional detail provided on vaccine dosage and administration for children & adults.

View Cholera

Diphtheria

Minor changes based on ATAGI advice. See Vaccination after tetanus-containing vaccines.

View Diphtheria

Haemophilus influenzae type b (Hib)

  • Updated guidance on route of administration.
  • Removal of Menitorix as vaccine was discontinued in July 2020.

Measles

Detailed guidance on vaccinating adults and children taking corticosteroids.

View Measles

Pertussis (whooping cough)

Clarification of advice regarding the minimum interval between a dTpa-containing vaccine after a dT-containing vaccine. See vaccination after tetanus containing vaccines.

Pneumococcal disease

Guidance for doses of 23vPPV required after a haematopoietic stem cell transplant updated.

Rabies and other lyssaviruses

Recommendations have been updated to allow intradermal vaccination and accelerated schedules for rabies pre-exposure prophylaxis.

Recommendations for people at ongoing exposure risk in selected high-risk occupations have been updated to specify a booster dose 1 year after completing the 1st course of pre-exposure prophylaxis, and every 3 years after that.

For post-exposure prophylaxis, recommendations have been updated to specify the number of vaccine doses and the need for human rabies immunoglobulin for people who are mildly immunocompromised and people who are severely immunocompromised.

Rotavirus

Additional guidance for infants receiving their 1st dose of rotavirus vaccine after the age cut-off.

View Rotavirus

Rubella

Minor changes to the recommended duration between vaccination and planned pregnancy from 3 months to 1 month.

View Rubella

Zoster (herpes zoster)

More detailed guidance provided on the use of Zostavax in people who are immunocompromised or on immunosuppressive therapy, including

  • more details on pre-vaccination screening, including serological testing for past varicella-zoster virus (VZV) infection where relevant
  • expanded list of immunosuppressive therapies that are considered safe for administration of Zostavax

Adverse events section updated to include:

  • detailed information on VZV-like rash that could rarely occur following Zostavax administration
  • relevant advice to vaccine recipients
  • management and reporting of these episodes